J&J Internal Ventures Group Focusing On Skin Patch, Stem Cell Therapies
Johnson & Johnson is using its J&J Internal Ventures group to identify and develop technologies to create a new skin patch
You may also be interested in...
Pfizer sees no need for significant changes to its sales force model for at least the next three to five years, CEO Hank McKinnell said Jan. 19
The Treasury Department and Internal Revenue Service will allow manufacturers to use repatriated cash from overseas operations on marketing expenses and mergers
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011